	US 12,458,049 B2
	Steviol glycoside solubility enhancers
Dan S. Gaspard, Victoria, MN (US); and Adam T. Zarth, St. Louis Park, MN (US)
Assigned to CARGILL, INCORPORATED, Wayzata, MN (US)
Filed by CARGILL, INCORPORATED, Wayzata, MN (US)
Filed on Jun. 20, 2022, as Appl. No. 17/807,798.
Application 17/807,798 is a continuation of application No. 16/373,206, filed on Apr. 2, 2019.
Application 16/373,206 is a continuation of application No. PCT/US2018/054691, filed on Oct. 5, 2018.
Claims priority of provisional application 62/676,722, filed on May 25, 2018.
Claims priority of provisional application 62/569,279, filed on Oct. 6, 2017.
Prior Publication US 2022/0323528 A1, Oct. 13, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A23L 27/30 (2016.01); A23F 3/34 (2006.01); A23L 2/56 (2006.01); A23L 2/60 (2006.01); A23L 2/68 (2006.01); A23L 5/40 (2016.01); A23L 27/00 (2016.01); A61K 31/192 (2006.01); A61K 31/235 (2006.01); A61K 36/28 (2006.01); B01D 15/36 (2006.01); C07H 15/256 (2006.01); C07K 1/16 (2006.01); C07K 1/18 (2006.01)

CPC A23L 27/36 (2016.08) [A23F 3/34 (2013.01); A23L 2/56 (2013.01); A23L 2/60 (2013.01); A23L 2/68 (2013.01); A23L 5/40 (2016.08); A23L 27/30 (2016.08); A23L 27/39 (2016.08); A23L 27/88 (2016.08); A61K 31/192 (2013.01); A61K 31/235 (2013.01); A61K 36/28 (2013.01); B01D 15/361 (2013.01); C07H 15/256 (2013.01); C07K 1/16 (2013.01); C07K 1/18 (2013.01); A23V 2002/00 (2013.01); A23V 2200/15 (2013.01); A23V 2250/258 (2013.01); A61K 2236/31 (2013.01); A61K 2236/39 (2013.01)]

21 Claims

1. An aqueous steviol glycoside solution comprising:

a) greater than 0.3% by weight of a total steviol glycoside composition comprising rebaudioside M, rebaudioside D, or combinations thereof; and

b) a steviol glycoside solubility enhancer composition in an amount such that the aqueous solution comprises a 1:0.3 to 1:3 ratio by weight of steviol glycoside to solubility enhancer composition, the steviol glycoside solubility enhancer composition comprising

i) one or more monocaffeoylquinic acids or salts thereof; and

ii) at least 20% by weight of one or more dicaffeoylquinic acids or salts thereof;

wherein the steviol glycoside remains in solution for at least 7 days at about 25° C.